肺纤方抗大鼠肺纤维化的实验研究  

The Experimental Study on Pulmonary Fibrosis Treated with FeixianFang in Rats

作　　者：张晓梅[1] 姜良铎[2] 张伟[2] 吴建军 鲁香凤[2] 

机构地区：[1]北京中医药大学东方医院,北京100078 [2]北京中医药大学东直门医院,北京100700 [3]北京王府医院,北京102209

出　　处：《中华中医药杂志》2007年第6期407-409,共3页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：2003-2006年北京科委课题(No.Y0204003041011)

摘　　要：目的:研究肺纤方与泼尼松对照抗大鼠肺纤维化肺组织病理的影响。方法:采用气管内注入博莱霉素的方法制造大鼠肺纤维化模型,观察造模后14、28、45d模型组、假手术组、肺纤方组、泼尼松组肺组织病理,光镜苏木精-伊红染色观察肺泡炎,光镜三色染色观察肺胶原。结果:肺纤方抗大鼠纤维化在45d尤为突出。结论:肺纤方有显著抗大鼠肺间质纤维化作用。Objective： To research the lung pathological changes of rats suffered from pulmonary fibrosis treated with FeixianFang compare with prednisene. Methods： After setting up the rat pulmonary fibrosis model by intratracheal injection of BLM for 14, 28, 45 days, the lung pathology was observed. HE staining was used for observation of airsacculitis, trichrome staining was used for observation of lung collogen under light microscope in the model group, the sham operation group, the FeixianFang group and the prednisone group. Results： The best effect of treating pulmonary fibrosis is on the 45th day with FeixlanFang administrated in rats. Conclusions： FeixiaFang has the significant effects on the treatment of pulmonary fibrosis of rats.

关 键 词：肺纤方 肺间质纤维化 博莱霉素纤维化模型 肺组织病理 

分 类 号：R285.5[医药卫生—中药学]